Correcting Sensory Processing in Fragile X Mice by Modulating Kv3.1

Correcting Sensory Processing in Fragile X Mice by Modulating Kv3.1

FRAXA has awarded a $90,000 grant to Carlos Portera-Cailliau, PhD and Nazim Kourdougli, PhD at UCLA to investigate whether a novel drug can rescue sensory processing deficits in Fragile X mice. People with Fragile X have similar problems in sensory processing. This new drug acts on Kv3.1, a promising Fragile X treatment target also being pursued by UK-based Autifony Therapeutics based on FRAXA-funded research done at Yale.

Read more

Imaging Synaptic Structure and Function in Fragile X Mice

Imaging Synaptic Structure and Function in Fragile X Mice

With in $150,000 grants from FRAXA Research Foundation over 2005-2009, Dr. Carlos Portera-Cailliau studied intact, anesthetized Fragile X mouse brains, looking for defects in the density, length, or dynamics of the dendrites. They looked for changes in the neurons after treatment with mGluR5 antagonists.

Read more